InvestWiserVistin Pharma ASA
VISTN · Oslo Børs · Healthcare
18.20NOK
−0.3%last day
Price as of 2 October 2026
Performance
1 month
−4.2%
1 year
−16.4%
3 years, per year
−3.4%
5 years, per year
+1.5%
Largest fall, 3 years
−29.0%
Below the peak now
−28.7%
Volatility, 1 year
25.0%
Return with dividends reinvested.
Key figures
P/E
11.8
P/B
2.6
Dividend yield
5.5%
Return on equity
+21.9%
Net margin
+16.2%
Market value
84 m USD
Quality, value and trend
Where Vistin Pharma stands against every Nordic stock today. 100 is best.
92
Profitability and a sound balance sheet over time. Better than 92% of Nordic stocks.
60
The price measured against earnings, assets and cash flow. Better than 60% of Nordic stocks.
22
The price development over the past year. Better than 22% of Nordic stocks.
63
Quality, value and trend together. Better than 63% of Nordic stocks.
About Vistin Pharma
Vistin Pharma ASA is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 74 employees.
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; metformin direct compressible; and metformin premixed with lubricant magnesium stearate for use in plain metformin immediate release tablets. The company was founded in 1969 and is based in Oslo, Norway.
See the full analysis in InvestWiser.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
See the full analysis